DYN

Over the past six months, Dyne Therapeutics' stock has been influenced by several events. Analyst ratings varied, with JPMorgan cutting its rating to 'underweight' and target to $10, Morgan Stanley lowering its target to $36 but maintaining 'overweight,' and Weiss Ratings reaffirming 'sell (d-).' Conversely, TD Cowen initiated with 'buy,' HC Wainwright reiterated 'buy' with a $50 target, and Raymond James reiterated 'Buy' with a $40 target. In July 2026, Dyne priced a public offering of 18.30 million shares at $20.50, expecting $375.15 million in gross proceeds. A selloff occurred in September 2026 following Novartis' Phase 3 failure of a rival myotonic dystrophy drug, though Dyne's shares later recovered as analysts noted differences in trial design. Also in September 2026, Dyne announced four new Duchenne muscular dystrophy exon-skipping candidates were advancing into IND-enabling studies. Dyne's shares rose in June 2026 after an amendment to its debt facility. Insider trading over the past three months primarily involved sales by Atlas Venture Advisors, Inc. and Erick Lucera (CFO), while Brian Posner made several purchases.